Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly

• On 31 March 2026, Nxera Pharma announced that its strategic partner, Centessa Pharmaceuticals, has entered a definitive agreement to be acquired by Eli Lilly & Co.
• Nxera retains all contractual rights to receive future milestone payments and tiered royalties on the OX2R agonist pipeline (cleminorexton, ORX142, ORX489) co-discovered with Centessa using Nxera’s NxStaR platform.
• Nxera holds an undisclosed equity stake in Centessa, which will convert to cash or Lilly shares upon deal closure.
• The release simultaneously highlights Nxera’s separate, pre-existing multi-target collaboration with Lilly, which carries up to US$694 million in potential development and commercial milestones plus tiered royalties.
• This announcement follows a sequence of operational updates: positive Phase 3 results for daridorexant in South Korea (Jan 2026), MAA submission in South Korea (Mar 2026), a US$3.6 million milestone receipt from Centessa (Jan 2026), and a US$40 million upfront licensing deal for vamorolone (Jan 2026).

• The Centessa-Lilly acquisition is a strategic validation of Nxera’s GPCR discovery platform and the OX2R mechanism, but it does not immediately alter Nxera’s operational control or near-term cash flow.
• The equity stake in Centessa represents a potential one-time liquidity event, but the size, lock-up terms, and conversion mechanics are undisclosed, making the financial impact unquantifiable at this stage.
• Royalty and milestone rights remain contractually intact, meaning Nxera benefits from Lilly’s superior commercial execution and capital depth without bearing development risk. However, these payments remain contingent on clinical and regulatory milestones that are years away.
• The news is incremental rather than transformative. It reinforces existing partnership economics but does not resolve Nxera’s high cash burn, delayed revenue recognition, or execution risks in new market launches.

• Nxera Pharma is a Japan-listed biopharmaceutical company focused on GPCR-targeted drug discovery and development, leveraging proprietary AI-enabled platforms (NxStaR, NxWave).
• Flagship commercial asset: Daridorexant (QUVIVIQ), a dual orexin receptor antagonist for insomnia, currently marketed in Japan via Shionogi, with expansion underway in South Korea and Taiwan.
• Pipeline spans multiple therapeutic areas: metabolic/obesity (oral GLP-1 agonist and six GPCR programs), oncology (HTL0039732 EP4 antagonist in Phase 2a), rare disease (vamorolone for DMD in Japan/APAC), and neuroscience (OX2R agonists with Centessa/Lilly, GPR52 agonist NXE’149).
• The company operates a partnership-heavy model, relying on out-licensing, milestone payments, and regional commercialization agreements rather than full vertical integration.